PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 2, 2012The Journal of Clinical Endocrinology & Metabolism173 citationsOpen Access

Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly

View Full Paper
FGFederico GattoRFRichard A. FeeldersRPRob van der Pas

Key Points

Key points are not available for this paper at this time.

Abstract

Sst2A IRS with the anti-sst2A antibody UMB-1 represents a valid tool in the clinical practice to identify acromegalic patients likely to be responders to adjuvant therapy with the currently available somatostatin analogs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gatto et al. (2012) studied this question.

synapsesocial.com/papers/69daa8f03bc1ef722568475ehttps://doi.org/10.1210/jc.2012-2609
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.2013 · 95 citations
  2. 2Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR2008 · 174 citations
  3. 3[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].1987 · 1,994 citations
  4. 4Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral Phenotypes12000 · 153 citations
  5. 5Guidelines for Acromegaly Management: An Update2009 · 764 citations